Claudia Amura
Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 3 | 2025 | 605 | 0.990 |
Why?
| | Opiate Substitution Treatment | 2 | 2025 | 189 | 0.800 |
Why?
| | Telemedicine | 4 | 2024 | 963 | 0.740 |
Why?
| | Needs Assessment | 1 | 2024 | 402 | 0.660 |
Why?
| | Buprenorphine | 2 | 2022 | 192 | 0.660 |
Why?
| | Cysts | 4 | 2009 | 112 | 0.620 |
Why?
| | Health Personnel | 1 | 2024 | 755 | 0.500 |
Why?
| | Liver Diseases | 3 | 2009 | 305 | 0.470 |
Why?
| | Reperfusion Injury | 3 | 2013 | 293 | 0.440 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 3 | 2009 | 235 | 0.420 |
Why?
| | Kidney Tubules | 2 | 2012 | 118 | 0.420 |
Why?
| | Macrophage Activation | 3 | 1998 | 181 | 0.380 |
Why?
| | Colorado | 6 | 2025 | 4556 | 0.370 |
Why?
| | Cyst Fluid | 3 | 2009 | 20 | 0.350 |
Why?
| | Complement Factor B | 1 | 2012 | 106 | 0.340 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 125 | 0.340 |
Why?
| | TRPP Cation Channels | 3 | 2009 | 74 | 0.330 |
Why?
| | Cytokines | 7 | 2012 | 2069 | 0.320 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 276 | 0.310 |
Why?
| | Complement Activation | 2 | 2012 | 399 | 0.310 |
Why?
| | Liver | 3 | 2008 | 1899 | 0.290 |
Why?
| | Pandemics | 4 | 2024 | 1711 | 0.280 |
Why?
| | Acute-Phase Proteins | 2 | 1998 | 66 | 0.270 |
Why?
| | HIV Infections | 1 | 2024 | 3195 | 0.270 |
Why?
| | Receptors, Interleukin-8B | 1 | 2008 | 29 | 0.270 |
Why?
| | Lipopolysaccharides | 5 | 1999 | 858 | 0.250 |
Why?
| | Pyrroles | 2 | 2009 | 220 | 0.250 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 109 | 0.250 |
Why?
| | Interleukin-8 | 1 | 2008 | 269 | 0.250 |
Why?
| | Cell Proliferation | 3 | 2009 | 2514 | 0.240 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2005 | 14 | 0.230 |
Why?
| | Epithelial Cells | 5 | 2012 | 1134 | 0.230 |
Why?
| | Membrane Glycoproteins | 2 | 1998 | 499 | 0.220 |
Why?
| | Neurofilament Proteins | 1 | 2005 | 79 | 0.220 |
Why?
| | Pluripotent Stem Cells | 1 | 2005 | 82 | 0.220 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 875 | 0.210 |
Why?
| | Indoles | 2 | 2009 | 507 | 0.200 |
Why?
| | Piroxicam | 5 | 1995 | 5 | 0.200 |
Why?
| | Program Development | 1 | 2025 | 368 | 0.200 |
Why?
| | Interleukin-1 | 3 | 1995 | 961 | 0.190 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 1998 | 1218 | 0.180 |
Why?
| | Membrane Proteins | 3 | 2010 | 1166 | 0.180 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6084 | 0.180 |
Why?
| | Midwifery | 1 | 2023 | 66 | 0.180 |
Why?
| | Labor Pain | 1 | 2022 | 12 | 0.180 |
Why?
| | Nitrous Oxide | 1 | 2022 | 34 | 0.180 |
Why?
| | Health Services Needs and Demand | 1 | 2024 | 280 | 0.170 |
Why?
| | Interviews as Topic | 1 | 2025 | 911 | 0.170 |
Why?
| | Analgesia, Obstetrical | 1 | 2022 | 33 | 0.170 |
Why?
| | Mice | 19 | 2013 | 18357 | 0.170 |
Why?
| | Cells, Cultured | 6 | 2012 | 4151 | 0.170 |
Why?
| | Program Evaluation | 1 | 2025 | 943 | 0.170 |
Why?
| | Chemotaxis, Leukocyte | 4 | 1995 | 114 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2025 | 309 | 0.160 |
Why?
| | Macrophages, Peritoneal | 2 | 1998 | 89 | 0.160 |
Why?
| | Pseudomonas aeruginosa | 5 | 1995 | 395 | 0.160 |
Why?
| | Academic Performance | 1 | 2021 | 15 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 660 | 0.160 |
Why?
| | Faculty, Nursing | 1 | 2021 | 31 | 0.160 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 910 | 0.160 |
Why?
| | Patient-Centered Care | 1 | 2025 | 547 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 1 | 2007 | 981 | 0.160 |
Why?
| | Education, Nursing, Graduate | 1 | 2021 | 37 | 0.160 |
Why?
| | Mice, Knockout | 5 | 2012 | 3130 | 0.160 |
Why?
| | Intimate Partner Violence | 1 | 2022 | 92 | 0.150 |
Why?
| | Crime Victims | 1 | 2022 | 131 | 0.150 |
Why?
| | Asthma | 2 | 2023 | 1797 | 0.150 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1101 | 0.150 |
Why?
| | Students, Nursing | 1 | 2021 | 93 | 0.140 |
Why?
| | Chemotactic Factors | 3 | 1993 | 43 | 0.140 |
Why?
| | Pilot Projects | 2 | 2022 | 1897 | 0.140 |
Why?
| | Humans | 22 | 2025 | 145750 | 0.140 |
Why?
| | Agranulocytosis | 2 | 1995 | 30 | 0.140 |
Why?
| | Kidney | 3 | 2013 | 1498 | 0.140 |
Why?
| | Lung Diseases | 2 | 1995 | 782 | 0.140 |
Why?
| | Perception | 1 | 2021 | 378 | 0.130 |
Why?
| | Animals | 26 | 2013 | 38100 | 0.130 |
Why?
| | Altitude | 1 | 2022 | 463 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 883 | 0.130 |
Why?
| | Carrier Proteins | 2 | 1998 | 729 | 0.130 |
Why?
| | Mice, Inbred C57BL | 6 | 2012 | 5992 | 0.130 |
Why?
| | Anti-Asthmatic Agents | 1 | 2019 | 260 | 0.120 |
Why?
| | Female | 19 | 2025 | 79025 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2024 | 947 | 0.120 |
Why?
| | Neurons | 1 | 2005 | 1652 | 0.120 |
Why?
| | Pseudomonas Infections | 2 | 1995 | 230 | 0.120 |
Why?
| | Neutrophils | 4 | 1995 | 1125 | 0.110 |
Why?
| | Sepsis | 2 | 1999 | 664 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2019 | 532 | 0.110 |
Why?
| | Mice, Inbred C3H | 4 | 1998 | 254 | 0.110 |
Why?
| | Signal Transduction | 4 | 2012 | 5223 | 0.110 |
Why?
| | Promoter Regions, Genetic | 3 | 2008 | 1247 | 0.100 |
Why?
| | Length of Stay | 1 | 2019 | 1350 | 0.100 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1154 | 0.090 |
Why?
| | Adult | 4 | 2025 | 40867 | 0.090 |
Why?
| | Male | 11 | 2025 | 72992 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2009 | 877 | 0.090 |
Why?
| | Immunity, Humoral | 1 | 2013 | 118 | 0.090 |
Why?
| | Copper | 1 | 1993 | 120 | 0.090 |
Why?
| | Health Behavior | 1 | 2018 | 789 | 0.090 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 419 | 0.090 |
Why?
| | Cell Line | 2 | 2008 | 2823 | 0.080 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 2383 | 0.080 |
Why?
| | Superoxide Dismutase | 1 | 1993 | 308 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2009 | 86 | 0.080 |
Why?
| | Complement Inactivator Proteins | 1 | 2010 | 39 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2018 | 638 | 0.080 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 76 | 0.080 |
Why?
| | Receptors, Complement | 1 | 2010 | 123 | 0.080 |
Why?
| | Complement Factor H | 1 | 2010 | 79 | 0.070 |
Why?
| | Graft Rejection | 1 | 2013 | 521 | 0.070 |
Why?
| | United States | 2 | 2025 | 16122 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2013 | 426 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2007 | 2028 | 0.070 |
Why?
| | Chemokine CXCL5 | 1 | 2008 | 19 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2009 | 552 | 0.070 |
Why?
| | Cell Shape | 1 | 2008 | 56 | 0.070 |
Why?
| | Chemokine CXCL1 | 1 | 2008 | 76 | 0.070 |
Why?
| | Antimicrobial Cationic Peptides | 2 | 1998 | 81 | 0.070 |
Why?
| | Blood Proteins | 3 | 1998 | 239 | 0.070 |
Why?
| | Injections, Intraperitoneal | 3 | 1998 | 116 | 0.060 |
Why?
| | Aged | 2 | 2025 | 26212 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1454 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2005 | 2051 | 0.060 |
Why?
| | Cell Hypoxia | 1 | 2008 | 247 | 0.060 |
Why?
| | Cell Polarity | 1 | 2008 | 137 | 0.060 |
Why?
| | Epithelial Sodium Channels | 1 | 2006 | 21 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2007 | 74 | 0.060 |
Why?
| | Bile Ducts | 1 | 2006 | 68 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 712 | 0.060 |
Why?
| | Mice, Neurologic Mutants | 1 | 2005 | 21 | 0.060 |
Why?
| | Wnt4 Protein | 1 | 2005 | 20 | 0.060 |
Why?
| | Exercise | 1 | 2018 | 2203 | 0.060 |
Why?
| | Stress, Mechanical | 1 | 2008 | 494 | 0.060 |
Why?
| | Transfection | 1 | 2008 | 927 | 0.060 |
Why?
| | Luciferases | 1 | 2005 | 154 | 0.060 |
Why?
| | Middle Aged | 2 | 2025 | 36297 | 0.060 |
Why?
| | Genes, Reporter | 1 | 2005 | 277 | 0.050 |
Why?
| | Embryo, Mammalian | 1 | 2005 | 234 | 0.050 |
Why?
| | Disease Models, Animal | 4 | 2009 | 4569 | 0.050 |
Why?
| | Wnt Proteins | 1 | 2005 | 133 | 0.050 |
Why?
| | Nerve Growth Factor | 1 | 2004 | 36 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2025 | 1202 | 0.050 |
Why?
| | Cadherins | 1 | 2005 | 200 | 0.050 |
Why?
| | Peroxidase | 2 | 1995 | 168 | 0.050 |
Why?
| | Down-Regulation | 1 | 2005 | 618 | 0.050 |
Why?
| | Time Factors | 4 | 2007 | 7133 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 751 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 1 | 2005 | 625 | 0.050 |
Why?
| | Certification | 1 | 2023 | 119 | 0.040 |
Why?
| | Tennessee | 1 | 2022 | 57 | 0.040 |
Why?
| | North Carolina | 1 | 2022 | 130 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2023 | 187 | 0.040 |
Why?
| | Nurse's Role | 1 | 2023 | 149 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2005 | 2805 | 0.040 |
Why?
| | Workflow | 1 | 2023 | 183 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 2181 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2006 | 777 | 0.040 |
Why?
| | House Calls | 1 | 2022 | 154 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 3551 | 0.040 |
Why?
| | Pregnancy | 2 | 2023 | 7215 | 0.040 |
Why?
| | Policy | 1 | 2020 | 149 | 0.040 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 1999 | 55 | 0.040 |
Why?
| | Thioglycolates | 1 | 1998 | 3 | 0.040 |
Why?
| | Galactosamine | 1 | 1998 | 3 | 0.040 |
Why?
| | Immune Sera | 1 | 1998 | 77 | 0.040 |
Why?
| | Monoamine Oxidase | 2 | 1975 | 27 | 0.040 |
Why?
| | Violence | 1 | 2022 | 280 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2025 | 736 | 0.030 |
Why?
| | Kinetics | 3 | 1998 | 1568 | 0.030 |
Why?
| | Blood Bactericidal Activity | 1 | 1997 | 38 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 1998 | 1368 | 0.030 |
Why?
| | Interleukin-12 | 1 | 1998 | 115 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 782 | 0.030 |
Why?
| | Adrenalectomy | 2 | 1975 | 68 | 0.030 |
Why?
| | Microsomes, Liver | 2 | 1979 | 85 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 424 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2019 | 251 | 0.030 |
Why?
| | Enzyme Activation | 1 | 1998 | 762 | 0.030 |
Why?
| | Immunization | 1 | 1998 | 375 | 0.030 |
Why?
| | Leadership | 1 | 2021 | 402 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 494 | 0.030 |
Why?
| | Interleukin-10 | 1 | 1998 | 310 | 0.030 |
Why?
| | Trypanosoma | 1 | 1975 | 8 | 0.030 |
Why?
| | Rats | 5 | 2004 | 5585 | 0.030 |
Why?
| | Child | 3 | 2023 | 22738 | 0.030 |
Why?
| | In Vitro Techniques | 3 | 1993 | 1049 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 558 | 0.030 |
Why?
| | Benzylamine Oxidase | 1 | 1975 | 1 | 0.030 |
Why?
| | Mothers | 1 | 2022 | 765 | 0.030 |
Why?
| | Child Behavior | 1 | 2018 | 236 | 0.030 |
Why?
| | Qualitative Research | 1 | 2023 | 1676 | 0.030 |
Why?
| | Acute-Phase Reaction | 1 | 1995 | 37 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2004 | 2601 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 431 | 0.030 |
Why?
| | ADP Ribose Transferases | 1 | 1995 | 9 | 0.030 |
Why?
| | Exotoxins | 1 | 1995 | 16 | 0.030 |
Why?
| | Parent-Child Relations | 1 | 2018 | 271 | 0.030 |
Why?
| | Monocytes | 1 | 1997 | 539 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1975 | 84 | 0.030 |
Why?
| | Mutation | 1 | 2005 | 4090 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 1995 | 108 | 0.030 |
Why?
| | Superoxides | 1 | 1995 | 198 | 0.030 |
Why?
| | Quality Improvement | 1 | 2023 | 1296 | 0.030 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1993 | 82 | 0.020 |
Why?
| | Copper Sulfate | 1 | 1993 | 8 | 0.020 |
Why?
| | Virulence Factors | 1 | 1995 | 175 | 0.020 |
Why?
| | Cytochrome c Group | 1 | 1993 | 43 | 0.020 |
Why?
| | Edetic Acid | 1 | 1993 | 47 | 0.020 |
Why?
| | Aggression | 1 | 1975 | 180 | 0.020 |
Why?
| | Antibody Formation | 2 | 2010 | 288 | 0.020 |
Why?
| | Registries | 1 | 2022 | 2410 | 0.020 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1992 | 62 | 0.020 |
Why?
| | Lung | 3 | 1995 | 4116 | 0.020 |
Why?
| | Edema | 1 | 1993 | 125 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 17322 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1850 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 1993 | 571 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2933 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 120 | 0.020 |
Why?
| | Receptors, Complement 3b | 1 | 2010 | 77 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1372 | 0.020 |
Why?
| | Transcription Factors | 1 | 1998 | 1736 | 0.020 |
Why?
| | Macrophages | 1 | 1998 | 1507 | 0.020 |
Why?
| | Peptidylprolyl Isomerase | 1 | 2009 | 9 | 0.020 |
Why?
| | NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 22 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 1992 | 346 | 0.020 |
Why?
| | Complement Pathway, Alternative | 1 | 2010 | 121 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2010 | 265 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1993 | 1068 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2447 | 0.020 |
Why?
| | Adolescent | 2 | 2019 | 22569 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 408 | 0.020 |
Why?
| | Birds | 1 | 1979 | 86 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1043 | 0.020 |
Why?
| | Pneumonia | 1 | 1994 | 636 | 0.020 |
Why?
| | Aniline Compounds | 1 | 1979 | 120 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 849 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1184 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 287 | 0.020 |
Why?
| | Receptors, Purinergic P2X4 | 1 | 2006 | 6 | 0.020 |
Why?
| | Amiloride | 1 | 2006 | 25 | 0.020 |
Why?
| | Receptors, Purinergic P2 | 1 | 2006 | 23 | 0.020 |
Why?
| | Ion Transport | 1 | 2006 | 62 | 0.020 |
Why?
| | Chlorine | 1 | 2006 | 59 | 0.020 |
Why?
| | Protein Binding | 2 | 2010 | 2240 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1723 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2006 | 396 | 0.010 |
Why?
| | Pentanones | 1 | 1975 | 3 | 0.010 |
Why?
| | Cyclic AMP | 1 | 2006 | 208 | 0.010 |
Why?
| | Digitoxin | 1 | 1975 | 5 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 821 | 0.010 |
Why?
| | Sodium | 1 | 2006 | 198 | 0.010 |
Why?
| | Enzyme Induction | 1 | 1975 | 88 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 1992 | 968 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 1992 | 926 | 0.010 |
Why?
| | Ketones | 1 | 1975 | 50 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 3 | 1979 | 532 | 0.010 |
Why?
| | Synapsins | 1 | 2004 | 13 | 0.010 |
Why?
| | PC12 Cells | 1 | 2004 | 42 | 0.010 |
Why?
| | Phosphorylation | 1 | 2009 | 1708 | 0.010 |
Why?
| | Young Adult | 1 | 2022 | 14250 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 153 | 0.010 |
Why?
| | Arginine | 1 | 1975 | 264 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 500 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2004 | 196 | 0.010 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 174 | 0.010 |
Why?
| | Antipsychotic Agents | 1 | 1976 | 211 | 0.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2004 | 254 | 0.010 |
Why?
| | Lysine | 1 | 1975 | 305 | 0.010 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 2 | 1993 | 38 | 0.010 |
Why?
| | Piperazines | 1 | 1975 | 375 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2004 | 372 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2009 | 956 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2004 | 317 | 0.010 |
Why?
| | Brain | 1 | 1975 | 2969 | 0.010 |
Why?
| | Schizophrenia | 1 | 1976 | 464 | 0.010 |
Why?
| | Proteins | 1 | 1975 | 1023 | 0.010 |
Why?
| | Antiviral Agents | 1 | 1975 | 769 | 0.010 |
Why?
| | Spermine | 1 | 1999 | 29 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1992 | 2667 | 0.010 |
Why?
| | Gram-Negative Bacteria | 1 | 1999 | 80 | 0.010 |
Why?
| | Neutralization Tests | 1 | 1998 | 76 | 0.010 |
Why?
| | Glycine | 1 | 1999 | 186 | 0.010 |
Why?
| | Hydroxylation | 2 | 1979 | 47 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1777 | 0.010 |
Why?
| | DNA Primers | 1 | 1998 | 505 | 0.010 |
Why?
| | Liver Glycogen | 1 | 1975 | 16 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1975 | 69 | 0.010 |
Why?
| | Ammonium Sulfate | 1 | 1975 | 8 | 0.010 |
Why?
| | Dopa Decarboxylase | 1 | 1975 | 1 | 0.010 |
Why?
| | Pimozide | 1 | 1975 | 3 | 0.010 |
Why?
| | Tubocurarine | 1 | 1975 | 6 | 0.010 |
Why?
| | Hydroxydopamines | 1 | 1975 | 4 | 0.010 |
Why?
| | Apomorphine | 1 | 1975 | 6 | 0.010 |
Why?
| | Carbachol | 1 | 1975 | 17 | 0.010 |
Why?
| | Dopamine beta-Hydroxylase | 1 | 1975 | 13 | 0.010 |
Why?
| | Acetylcholinesterase | 1 | 1975 | 10 | 0.010 |
Why?
| | Dihydroxyphenylalanine | 1 | 1975 | 11 | 0.010 |
Why?
| | Parasympatholytics | 1 | 1975 | 11 | 0.010 |
Why?
| | Amantadine | 1 | 1975 | 8 | 0.010 |
Why?
| | Choline O-Acetyltransferase | 1 | 1975 | 26 | 0.010 |
Why?
| | Monoamine Oxidase Inhibitors | 1 | 1975 | 20 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1975 | 24 | 0.010 |
Why?
| | Cholinesterase Inhibitors | 1 | 1975 | 47 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1998 | 784 | 0.010 |
Why?
| | Base Sequence | 1 | 1998 | 2171 | 0.010 |
Why?
| | Dogs | 1 | 1975 | 478 | 0.010 |
Why?
| | Nitric Oxide | 1 | 1998 | 892 | 0.010 |
Why?
| | Culture Media | 1 | 1993 | 161 | 0.010 |
Why?
| | Aerosols | 1 | 1993 | 145 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 246 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1993 | 638 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1998 | 1505 | 0.010 |
Why?
| | Glucose | 1 | 1975 | 1048 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1992 | 1261 | 0.000 |
Why?
| | Dealkylation | 1 | 1979 | 3 | 0.000 |
Why?
| | Oxidoreductases, N-Demethylating | 1 | 1979 | 17 | 0.000 |
Why?
| | Inactivation, Metabolic | 1 | 1979 | 9 | 0.000 |
Why?
| | Phenotype | 1 | 1998 | 3170 | 0.000 |
Why?
| | Combined Modality Therapy | 1 | 1992 | 1270 | 0.000 |
Why?
| | Species Specificity | 1 | 1979 | 546 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1979 | 563 | 0.000 |
Why?
| | Promazine | 1 | 1976 | 1 | 0.000 |
Why?
| | Trifluoperazine | 1 | 1976 | 3 | 0.000 |
Why?
| | Chlorpromazine | 1 | 1976 | 5 | 0.000 |
Why?
| | Basal Ganglia Diseases | 1 | 1976 | 9 | 0.000 |
Why?
| | Micrococcus | 1 | 1975 | 4 | 0.000 |
Why?
| | Digitoxigenin | 1 | 1975 | 3 | 0.000 |
Why?
| | Tyrosine Transaminase | 1 | 1975 | 4 | 0.000 |
Why?
| | Chromatography, Thin Layer | 1 | 1975 | 24 | 0.000 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 1975 | 81 | 0.000 |
Why?
| | Cortisone | 1 | 1975 | 16 | 0.000 |
Why?
| | Culture Techniques | 1 | 1975 | 66 | 0.000 |
Why?
| | NADP | 1 | 1975 | 52 | 0.000 |
Why?
| | Muramidase | 1 | 1975 | 67 | 0.000 |
Why?
| | Tryptophan Oxygenase | 1 | 1975 | 33 | 0.000 |
Why?
| | Movement Disorders | 1 | 1976 | 69 | 0.000 |
Why?
| | Tyrosine | 1 | 1975 | 217 | 0.000 |
Why?
| | Imidazoles | 1 | 1975 | 247 | 0.000 |
Why?
| | Protein Conformation | 1 | 1975 | 938 | 0.000 |
Why?
| | Binding Sites | 1 | 1975 | 1311 | 0.000 |
Why?
| | Recurrence | 1 | 1976 | 1139 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1976 | 1062 | 0.000 |
Why?
| | Chronic Disease | 1 | 1976 | 1810 | 0.000 |
Why?
|
|
Amura's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|